Bank of New York Mellon’s ArriVent BioPharma AVBP Stock Holding History

Bank of New York Mellon’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.61M	Buy	103,931 +28,483	+38%	+$841K	﹤0.01%	2633
2026 Q1	$1.74M	Buy	75,448 +2,337	+3%	+$52.8K	﹤0.01%	2885
2025 Q4	$1.47M	Buy	73,111 +9,828	+16%	+$205K	﹤0.01%	3018
2025 Q3	$1.17M	Buy	63,283 +4,505	+8%	+$88.5K	﹤0.01%	3121
2025 Q2	$1.28M	Sell	58,778 -9,447	-14%	-$196K	﹤0.01%	2987
2025 Q1	$1.26M	Buy	68,225 +222	+0.3%	+$5.43K	﹤0.01%	2922
2024 Q4	$1.81M	Sell	68,003 -318	-0.5%	-$9.13K	﹤0.01%	2797
2024 Q3	$1.61M	Buy	68,321 +38,474	+129%	+$873K	﹤0.01%	2857
2024 Q2	$554K	Buy	29,847 +7,140	+31%	+$127K	﹤0.01%	3528
2024 Q1	$406K	Buy	+22,707	New	+$458K	﹤0.01%	3650

Other funds holding AVBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Bank of New York Mellon's AVBP Position: Q2 2026 in Review

Bank of New York Mellon increased its ArriVent BioPharma (AVBP) stake by 38% in Q2 2026, buying an estimated $841K and bringing the position to 103,931 shares worth $3.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2633.

Bank of New York Mellon first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 47 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Bank of New York Mellon held 103,931 shares of ArriVent BioPharma worth $3.61M as of Q2 2026.
Bank of New York Mellon bought 28,483 ArriVent BioPharma shares in Q2 2026, an estimated $841K.
ArriVent BioPharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2633 holding.
Bank of New York Mellon first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
47 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.